GlassScriptPhysician profile
Juan R Herena
NPI 1922167162
$14,002.70
in general payments reported to CMS, 2019-2025
40 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,124 · 2020: $1,249 · 2021: $1,530 · 2022: $2,724 · 2023: $3,711 · 2024: $1,984 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,375.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,653.97 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,975.58 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $1,868.15 | 2019-2024 | Fasenra, Airsupra, Tezspire |
| Harmony Biosciences LLC | $959.28 | 2020-2024 | Wakix |
| Electromed, INC. | $643.76 | 2019-2024 | Smartvest |
| Mylan Specialty L.P. | $595.48 | 2019-2024 | Yupelri |
| Genzyme Corporation | $522.59 | 2021-2024 | |
| Grifols USA, LLC | $404.58 | 2019-2023 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $367.82 | 2023-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $295.48 | 2022-2024 | Glassia |
| Vanda Pharmaceuticals INC. | $259.71 | 2020-2023 | Hetlioz |
| Philips North America LLC | $234.94 | 2019-2025 | (Ak6) Vest Therapy, (8874) Incourage, Patient Interface Software |
| Baxter Healthcare | $208.24 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $205.17 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $190.70 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $169.12 | 2019-2023 | Arikayce |
| Mallinckrodt Hospital Products INC. | $155.22 | 2022-2023 | Acthar |
| Pulmonx Corporation | $139.57 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Regeneron Healthcare Solutions, INC. | $132.18 | 2021-2024 | Dupixent |
| Lilly USA, LLC | $125.00 | 2025 | Zepbound |
| Amgen INC. | $108.42 | 2023-2024 | Tezspire |
| Sunovion Pharmaceuticals INC. | $107.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $95.61 | 2021-2023 | Uptravi, Opsumit |
| Axsome Therapeutics, INC. | $77.92 | 2023-2024 | Sunosi |
| Covis Pharma Gmbh | $63.85 | 2022 | |
| Shionogi INC | $57.49 | 2023 | Fetroja |
| United Therapeutics Corporation | $47.82 | 2023-2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $38.47 | 2019 | |
| Mayne Pharma Commercial LLC | $37.35 | 2019 | |
| Tactile Systems Technology INC | $33.18 | 2024 | Entre Plus, Flexitouch Plus |
| Advanced Respiratory, INC | $32.93 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $31.90 | 2021 | |
| Eisai INC. | $31.03 | 2021 | |
| Circassia INC. | $28.96 | 2019 | |
| Breas Medical, INC. | $21.57 | 2023 | Vivo 45 Ls |
| Inogen, INC. | $20.45 | 2022 | |
| Melinta Therapeutics, LLC | $17.10 | 2024 | Rezzayo |
| Vapotherm INC | $15.40 | 2021 | |
| Pfizer INC. | $14.59 | 2019 | |
| Csl Behring | $14.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Herena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.